The invention comprises a slow release hydrogel formulation for sustained, localized, and controlled delivery of therapeutics to the middle and/or inner ear.
Treatment of middle and inner ear pathologies is a very large area of unmet need, as most current strategies fail to deliver a high-level and localized sustained dose of a therapeutic to the areas.
This technology, which overcomes the localized high-dose delivery hurdle, has the potential of being useful in the treatment of middle ear and inner ear pathologies, including Meniere’s Disease. The hydrogel slowly degrades over time as it delivers its therapeutic cargo, and was also developed to allow it to be quickly degraded and washed out in emergency situations through the application of an exogenously applied enzyme.
Pending US rights
J Control Release. 2013 Mar 28;166(3):268-76.
- Direct licensing
Docket # U4595